Get the Stockscreener App
8.29
0.36%
-0.03
After Hours:
8.29
Prothena Corp Plc stock is traded at $8.29, with a volume of 481.05K.
It is down -0.36% in the last 24 hours and down -12.00% over the past month.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
See More
Previous Close:
$8.32
Open:
$8.38
24h Volume:
481.05K
Relative Volume:
0.98
Market Cap:
$425.58M
Revenue:
$57.94M
Net Income/Loss:
$-151.18M
P/E Ratio:
-2.9485
EPS:
-2.8116
Net Cash Flow:
$-86.56M
1W Performance:
-3.38%
1M Performance:
-12.00%
6M Performance:
-10.96%
1Y Performance:
-11.43%
1-Day Range:
$8.185
$8.52
1-Week Range:
$8.185
$9.09
52-Week Range:
$7.73
$11.80
Prothena Corp Plc Stock (PRTA) Company Profile
Name
Prothena Corp Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corp Plc
|
8.29 | 425.58M | 57.94M | -151.18M | -86.56M | -2.8116 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corp Plc Stock (PRTA) Latest News
Form 4 PROTHENA CORP PUBLIC LTD CO For: 27 September By Investing.com - Investing.com UK
Trading Systems Reacting to (PRTA) Volatility - Stock Traders Daily
Prothena stock falls to USD 8.51 as earnings beat estimates - ad-hoc-news.de
Prothena Corporation plc (PRTA) Stock Analysis: Unveiling a 153% Upside Potential Amidst Biotech Challenges - DirectorsTalk Interviews
Prothena (PRTA) Stock: Falls -2.58% — Where's the Floor? 2026-09-10Fear Greed Extreme - siam.in
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Business Wire
Prothena stock holds near USD 9.60 after market cap update - ad-hoc-news.de
Responsive Playbooks and the PRTA Inflection - Stock Traders Daily
Prothena Corporation plc (PRTA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Prothena Corporation plc (PRTA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Prothena Corporation plc (PRTA) Key Financial Ratios – Valuation, Profitability & More - Value Research
Prothena Stock Price Forecast. Should You Buy PRTA? - StockInvest.us
Prothena (NASDAQ:PRTA) Major Shareholder Buys 50,000 Shares of Stock - MarketBeat
Prothena (NASDAQ:PRTA) Shares Pass Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Prothena (PRTA) Holds Steady Near $8.88 as Shares Sit Between Key Support and ResistancePositive Gamma - vinanet.vn
Precision Trading with Prothena Corporation Plc (PRTA) Risk Zones - Stock Traders Daily
PRTA Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 9.7% EPS SurpriseGuidance Revision Trend - careplusvn.com
HC Wainwright Issues Positive Estimate for Prothena Earnings - MarketBeat
Weekly Recap: Q2 loss, cash and burn outlook and Partner trial timelines - TradingView
Prothena (PRTA) Stock Shrugs Off Revenue Drop As Pipeline Stakes Rise - Sahm
Prothena Corporation PLC (PRTA) Stock News Today - TradingKey
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - tradingview.com
Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Prothena Corporation PLC reports results for the quarter ended June 30Earnings Summary - tradingview.com
Prothena: Q2 Earnings Snapshot - marketscreener.com
Prothena (NASDAQ: PRTA) turns H1 2026 profit on $50M milestone - Stock Titan
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights - marketscreener.com
FMR LLC discloses 13.8% Prothena (PRTA) ownership; key fund holds 6.4% - stocktitan.net
Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA - MarketBeat
Prothena (PRTA) Holds Ground at $8.49: Consolidation Between Key LevelsVolatility Stop - careplusvn.com
Prothena Corporation PLC expected to post a loss of 39 cents a shareEarnings Preview - tradingview.com
PRTA Q1 2026 Earnings: EPS of $0.61 Beats Estimate by 271.69% as Shares Slip 3.45%Consensus Beat Rate - careplusvn.com
Technical Reactions to PRTA Trends in Macro Strategies - Stock Traders Daily
Prothena (NASDAQ:PRTA) Insider Anne Evans Kingston Sells 7,662 Shares of Stock - MarketBeat
Prothena Corp PLC (PRTA) Chief Strategy Officer Anne Kingston Se - GuruFocus
Prothena to Report Second Quarter 2026 Financial Results on August 6 - Business Wire
BlackRock (PRTA holder) discloses 6.9% beneficial stake in Prothena common stock - Stock Titan
Prothena Corp. Plc Revenue Breakdown – LSX:A1KAVV - TradingView
Rubric Capital Management LP Has $48.60 Million Position in Prothena Corporation plc $PRTA - MarketBeat
Prothena Corporation PLC (PRTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Top Growth Companies With Insider Ownership For July 2026 - simplywall.st
Prothena (PRTA) Rallies 2.58%: Support Holds as Biotech Stock Rebounds from LowsIsland Reversal - careplusvn.com
Prothena stock trades steady as Alzheimer portfolio advances and earnings show growing R&D investmen - Ad-hoc-news.de
Trading the Move, Not the Narrative: (PRTA) Edition - Stock Traders Daily
Michael John Isaacs Net Worth (2026) - GuruFocus
Prothena (PRTA) Holds Steady Near Support as Biotech Sector Eyes Key CatalystOutside Reversal - vinanet.vn
Prothena (PRTA) Price Target Increased by 37.50% to 16.83 - msn.com
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? - Yahoo Finance
Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepens - ad-hoc-news.de
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
Prothena Corp Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):